NYSE:JNJ - Johnson & Johnson Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $190.38
  • Forecasted Upside: 9.81 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$173.36
▼ -1.03 (-0.59%)

This chart shows the closing price for JNJ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Johnson & Johnson Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JNJ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JNJ

Analyst Price Target is $190.38
▲ +9.81% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Johnson & Johnson in the last 3 months. The average price target is $190.38, with a high forecast of $200.00 and a low forecast of $175.00. The average price target represents a 9.81% upside from the last price of $173.36.

This chart shows the closing price for JNJ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in Johnson & Johnson. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/11/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/11/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/9/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/7/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/5/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/6/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/5/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/29/2021SVB LeerinkReiterated RatingBuyLow
7/21/2021SVB LeerinkReiterated RatingOutperformLow
6/7/2021Credit Suisse GroupSet Price TargetBuy$193.00Low
6/1/2021Credit Suisse GroupSet Price TargetBuy$193.00High
5/28/2021Morgan StanleyInitiated CoverageOverweight$187.00Low
1/27/2021JPMorgan Chase & Co.Boost Price TargetNeutral$157.00 ➝ $175.00Medium
1/27/2021Credit Suisse GroupBoost Price TargetOutperform$168.00 ➝ $193.00Medium
1/27/2021Raymond JamesBoost Price TargetOutperform$158.00 ➝ $183.00Medium
1/27/2021CowenBoost Price TargetOutperform$170.00 ➝ $195.00Medium
1/27/2021Morgan StanleyBoost Price TargetOverweight$178.00 ➝ $187.00Medium
1/27/2021SVB LeerinkBoost Price TargetOutperform$180.00 ➝ $200.00Medium
1/27/2021Wells Fargo & CompanyBoost Price TargetPositive ➝ Overweight$175.00 ➝ $190.00Medium
1/26/2021Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$180.00 ➝ $200.00Medium
12/15/2020Morgan StanleyBoost Price TargetOverweight$170.00 ➝ $178.00Low
11/20/2020Raymond JamesReiterated RatingBuyMedium
10/14/2020Credit Suisse GroupBoost Price TargetPositive ➝ Outperform$163.00 ➝ $168.00Low
10/14/2020Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$168.00 ➝ $180.00Low
10/13/2020Credit Suisse GroupSet Price TargetBuy$163.00Low
9/4/2020Credit Suisse GroupReiterated RatingBuyMedium
8/19/2020Stifel NicolausDowngradeBuy ➝ HoldLow
8/3/2020Cantor FitzgeraldReiterated RatingBuy$168.00Low
7/20/2020Bank of AmericaReiterated RatingBuyLow
7/20/2020Independent ResearchUpgradeHold ➝ Buy$161.00 ➝ $164.00Low
7/17/2020Raymond JamesBoost Price TargetOutperform$157.00 ➝ $158.00Medium
7/17/2020CitigroupBoost Price TargetBuy$165.00 ➝ $170.00Low
7/15/2020SVB LeerinkReiterated RatingOutperformMedium
4/29/2020Morgan StanleyBoost Price TargetOverweight$160.00 ➝ $170.00Low
4/29/2020BarclaysBoost Price TargetOverweight$173.00 ➝ $182.00Low
4/28/2020Cantor FitzgeraldReiterated RatingBuy$168.00Low
4/28/2020Credit Suisse GroupReiterated RatingBuy$161.00Low
4/28/2020UBS GroupDowngradeBuy ➝ Neutral$163.00 ➝ $160.00Medium
4/22/2020Wells Fargo & CompanyUpgradeHoldMedium
4/22/2020Bank of AmericaUpgradeNeutral ➝ Buy$150.00 ➝ $175.00Low
4/15/2020Stifel NicolausBoost Price TargetHold$140.00 ➝ $155.00Medium
4/15/2020Wells Fargo & CompanyBoost Price TargetOverweight$150.00 ➝ $162.00Medium
4/15/2020CitigroupBoost Price TargetBuy$150.00 ➝ $165.00Medium
4/15/2020Raymond JamesBoost Price TargetOutperform$153.00 ➝ $157.00Low
4/15/2020Credit Suisse GroupBoost Price TargetOutperform$155.00 ➝ $161.00Low
4/9/2020Raymond JamesLower Price TargetOutperform$161.00 ➝ $153.00Low
4/8/2020SVB LeerinkLower Price TargetOutperform$172.00 ➝ $160.00High
4/3/2020Cantor FitzgeraldReiterated RatingBuy$168.00High
4/2/2020Wells Fargo & CompanyLower Price TargetOverweight$165.00 ➝ $150.00Medium
4/1/2020Stifel NicolausLower Price TargetHold$155.00 ➝ $140.00Low
3/27/2020Morgan StanleyLower Price TargetOverweight$170.00 ➝ $160.00Medium
3/27/2020CitigroupLower Price TargetBuy$163.00 ➝ $150.00Low
3/27/2020ArgusReiterated RatingBuy$165.00 ➝ $155.00Low
3/6/2020Credit Suisse GroupLower Price TargetOutperform$170.00 ➝ $159.00Medium
3/4/2020CitigroupInitiated CoverageBuy$163.00Low
2/17/2020Credit Suisse GroupReiterated RatingBuy$170.00Medium
1/27/2020Credit Suisse GroupBoost Price TargetOutperform$163.00 ➝ $170.00Low
1/23/2020Cantor FitzgeraldReiterated RatingBuy$168.00Low
1/23/2020Raymond JamesBoost Price TargetOutperform$147.00 ➝ $161.00Low
1/9/2020Wells Fargo & CompanyBoost Price TargetOverweight$155.00 ➝ $165.00Low
12/31/2019Credit Suisse GroupReiterated RatingBuy$163.00Low
12/19/2019BarclaysUpgradeEqual Weight ➝ Overweight$140.00 ➝ $173.00Medium
12/17/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$145.00 ➝ $170.00Low
11/27/2019Cantor FitzgeraldInitiated CoverageOverweight$160.00Low
11/19/2019Cantor FitzgeraldInitiated CoverageOverweight$160.00 ➝ $160.00Low
10/24/2019Credit Suisse GroupBoost Price Target$158.00 ➝ $163.00Low
10/16/2019Credit Suisse GroupBoost Price TargetOutperform$156.00 ➝ $158.00Medium
10/16/2019Wells Fargo & CompanyLower Price TargetOutperform$157.00 ➝ $155.00Medium
10/16/2019Atlantic SecuritiesUpgradeUnderweight ➝ NeutralMedium
10/14/2019Raymond JamesLower Price TargetOutperform$146.00 ➝ $145.00Low
10/11/2019Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$155.00Low
8/27/2019The Goldman Sachs GroupSet Price TargetBuy$169.00Medium
8/27/2019Morgan StanleyReiterated RatingEqual Weight$145.00High
8/27/2019Credit Suisse GroupSet Price TargetBuy$156.00Low
7/18/2019Credit Suisse GroupSet Price TargetBuy$156.00Low
7/17/2019Raymond JamesLower Price TargetOutperform$147.00 ➝ $146.00Low
7/16/2019Royal Bank of CanadaReiterated RatingBuyLow
7/16/2019Bank of AmericaReiterated RatingHold$150.00Low
7/12/2019Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$156.00High
6/21/2019BarclaysInitiated CoverageHold$140.00Low
5/28/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ BuyHigh
5/16/2019Credit Suisse GroupBoost Price TargetOutperform$152.00 ➝ $156.00Low
5/6/2019Wells Fargo & CompanyReiterated RatingOutperform$152.00 ➝ $157.00Low
4/17/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$154.00 ➝ $157.00Low
4/17/2019Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$151.00 ➝ $152.00Low
4/17/2019Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$134.00 ➝ $145.00Low
4/17/2019Raymond JamesBoost Price TargetOutperform ➝ Outperform$145.00 ➝ $147.00Low
2/25/2019CitigroupBoost Price TargetNeutral ➝ Neutral$139.00 ➝ $147.00Low
1/23/2019BarclaysReiterated RatingEqual Weight ➝ Equal Weight$137.00 ➝ $135.00High
1/14/2019Wells Fargo & CompanyReiterated RatingOutperform ➝ Outperform$162.00 ➝ $152.00Low
1/2/2019Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$153.00 ➝ $130.00Low
1/2/2019CitigroupLower Price TargetNeutral ➝ Neutral$148.00 ➝ $139.00Low
12/20/2018Morgan StanleySet Price TargetHold$140.00Low
10/22/2018CitigroupBoost Price TargetNeutral ➝ Neutral$137.00 ➝ $148.00Low
10/17/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$149.00 ➝ $152.00Medium
10/17/2018Raymond JamesBoost Price TargetOutperform ➝ Outperform$144.00 ➝ $149.00Medium
10/17/2018Wells Fargo & CompanyReiterated RatingOutperform$155.00 ➝ $160.00Medium
10/17/2018HC WainwrightReiterated RatingBuyHigh
10/14/2018Credit Suisse GroupSet Price TargetBuy$149.00Low
9/14/2018Wells Fargo & CompanyReiterated RatingOutperform$160.00Low
7/15/2018Jefferies Financial GroupSet Price TargetBuy$145.00Medium
7/13/2018Credit Suisse GroupSet Price TargetBuy$151.00Medium
7/12/2018The Goldman Sachs GroupUpgradeSell ➝ NeutralLow
6/27/2018Sanford C. BernsteinInitiated CoverageMarket Perform$129.00Low
6/12/2018Credit Suisse GroupSet Price TargetBuy$151.00Low
4/23/2018CitigroupLower Price TargetNeutral$146.00 ➝ $134.00Low
4/20/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$154.00 ➝ $151.00Low
4/18/2018Wells Fargo & CompanyReiterated RatingOutperform$160.00 ➝ $150.00High
4/18/2018Stifel NicolausLower Price TargetHold ➝ Hold$145.00 ➝ $135.00High
4/18/2018SVB LeerinkReiterated RatingOutperform$175.00 ➝ $160.00High
4/18/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyHigh
4/17/2018Credit Suisse GroupSet Price TargetBuy$154.00High
4/17/2018The Goldman Sachs GroupSet Price TargetSell$134.00Low
4/13/2018Jefferies Financial GroupSet Price TargetBuy$153.00Low
4/10/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$148.00 ➝ $143.00Low
3/23/2018Jefferies Financial GroupSet Price TargetBuy$161.00Medium
2/27/2018CitigroupLower Price TargetNeutral ➝ Neutral$150.00 ➝ $146.00Medium
2/26/2018Jefferies Financial GroupSet Price TargetBuy$165.00Low
1/24/2018Stifel NicolausBoost Price TargetHold ➝ Hold$142.00 ➝ $145.00Low
1/24/2018BTIG ResearchReiterated RatingSell$110.00Low
1/22/2018Credit Suisse GroupSet Price TargetHold$154.00High
1/12/2018Wells Fargo & CompanyReiterated RatingOutperform ➝ Outperform$155.00 ➝ $160.00Low
1/9/2018Royal Bank of CanadaReiterated RatingBuyLow
1/2/2018JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
12/12/2017BMO Capital MarketsBoost Price TargetOutperform$161.00Medium
10/23/2017CitigroupBoost Price TargetBuy$140.00 ➝ $149.00N/A
10/19/2017Credit Suisse GroupSet Price TargetOutperform$147.00 ➝ $154.00N/A
10/18/2017BarclaysBoost Price TargetEqual Weight$140.00 ➝ $148.00N/A
10/18/2017CowenReiterated RatingOutperform$147.00 ➝ $155.00N/A
10/18/2017Morgan StanleyReiterated RatingHold$140.00 ➝ $145.00N/A
10/18/2017ArgusBoost Price TargetBuy ➝ Positive$145.00 ➝ $165.00N/A
10/18/2017Wells Fargo & CompanyReiterated RatingOutperform$149.00 ➝ $155.00N/A
10/18/2017BMO Capital MarketsReiterated RatingOutperform ➝ Positive$145.00 ➝ $152.00N/A
10/18/2017Stifel NicolausBoost Price TargetHold ➝ Hold$140.00 ➝ $142.00N/A
10/18/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$144.00 ➝ $147.00N/A
10/18/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$150.00 ➝ $165.00N/A
10/16/2017Jefferies Financial GroupBoost Price TargetBuy$157.00 ➝ $160.00N/A
10/11/2017Jefferies Financial GroupUpgradeHold ➝ Buy$145.00 ➝ $157.00N/A
10/9/2017Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$140.00 ➝ $149.00N/A
10/6/2017CowenSet Price TargetBuy$147.00N/A
10/4/2017Piper Jaffray CompaniesReiterated RatingHold$120.00Low
9/30/2017UBS GroupReiterated RatingBuy$148.00Low
9/25/2017CitigroupInitiated CoverageNeutral ➝ Neutral$140.00Low
9/20/2017The Goldman Sachs GroupDowngradeNeutral ➝ Sell$125.00 ➝ $130.00Low
9/1/2017BMO Capital MarketsReiterated RatingBuy$145.00N/A
8/31/2017UBS GroupReiterated RatingBuy$148.00Low
8/24/2017UBS GroupReiterated RatingUnderweightLow
8/24/2017CowenSet Price TargetBuy$147.00Low
8/16/2017JPMorgan Chase & Co.Boost Price TargetOverweight$140.00 ➝ $148.00Low
8/15/2017Jefferies Financial GroupSet Price TargetHold$145.00Low
8/4/2017Credit Suisse GroupReiterated RatingBuyLow
7/21/2017Alembic Global AdvisorsDowngradeNeutral ➝ UnderweightLow
7/21/2017Atlantic SecuritiesDowngradeNeutral ➝ Underweight$113.00Low
7/21/2017BTIG ResearchDowngradeNeutral ➝ Sell$110.00Low
7/20/2017Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$148.00Medium
7/19/2017UBS GroupReiterated RatingBuy$136.00 ➝ $148.00Low
7/14/2017Jefferies Financial GroupReiterated RatingHold$140.00 ➝ $145.00Low
7/12/2017Royal Bank of CanadaReiterated RatingBuy$138.00Medium
7/6/2017Wells Fargo & CompanyReiterated RatingMarket Perform$132.00 ➝ $135.00Low
7/5/2017Morgan StanleyBoost Price TargetOverweight$135.00 ➝ $140.00Low
6/16/2017Jefferies Financial GroupReiterated RatingHold$140.00Medium
6/15/2017Royal Bank of CanadaReiterated RatingBuy$128.00Medium
6/13/2017CowenReiterated RatingOutperform$143.00Low
6/2/2017BMO Capital MarketsReiterated RatingBuy$132.00Low
5/21/2017BTIG ResearchReiterated RatingHoldLow
5/19/2017Morgan StanleyReiterated RatingEqual Weight$130.00 ➝ $135.00Low
5/19/2017CowenReiterated RatingBuy$138.00 ➝ $143.00Low
5/18/2017Stifel NicolausReiterated RatingHold ➝ Hold$124.00 ➝ $128.00Low
5/15/2017UBS GroupReiterated RatingBuy$136.00N/A
5/15/2017JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$123.64 ➝ $140.00High
5/14/2017Jefferies Financial GroupReiterated RatingHold$140.00 ➝ $135.00High
4/19/2017BTIG ResearchReiterated RatingHoldLow
4/17/2017BarclaysReiterated RatingEqual Weight$125.00 ➝ $130.00Low
3/11/2017Jefferies Financial GroupReiterated RatingHold$125.00 ➝ $132.00N/A
1/26/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$112.28 ➝ $112.80N/A
1/25/2017UBS GroupLower Price TargetBuy$142.00 ➝ $141.00N/A
1/25/2017Royal Bank of CanadaLower Price TargetOutperform$133.00 ➝ $128.00N/A
1/25/2017The Goldman Sachs GroupLower Price TargetNeutral$120.00 ➝ $115.00N/A
1/20/2017Jefferies Financial GroupBoost Price TargetHold$110.00 ➝ $120.00N/A
1/6/2017Royal Bank of CanadaReiterated RatingBuy$133.00N/A
1/5/2017Jefferies Financial GroupReiterated RatingHold$107.00 ➝ $110.00N/A
12/20/2016Credit Suisse GroupReiterated RatingHoldN/A
12/20/2016Jefferies Financial GroupReiterated RatingHold$107.00N/A
11/29/2016BarclaysDowngradeOverweight ➝ Equal Weight$130.00 ➝ $125.00N/A
11/28/2016Bank of AmericaReiterated RatingHold$126.00N/A
11/28/2016UBS GroupReiterated RatingBuy$144.00N/A
11/9/2016Royal Bank of CanadaSet Price TargetBuy$133.00N/A
10/23/2016Societe GeneraleReiterated RatingHold$116.00N/A
10/21/2016ArgusReiterated RatingBuy$145.00N/A
10/19/2016UBS GroupReiterated RatingBuy$137.00 ➝ $144.00N/A
9/28/2016UBS GroupReiterated RatingBuy$137.00N/A
9/20/2016UBS GroupReiterated RatingBuy$137.00N/A
9/19/2016Credit Suisse GroupReiterated RatingNeutral$123.00N/A
9/13/2016Jefferies Financial GroupLower Price TargetHold$119.00 ➝ $115.00N/A
9/11/2016SVB LeerinkReiterated RatingBuyN/A
9/7/2016BTIG ResearchReiterated RatingNeutralN/A
9/7/2016UBS GroupReiterated RatingBuyN/A
8/25/2016BTIG ResearchReiterated RatingNeutralN/A
8/22/2016UBS GroupReiterated RatingBuyN/A
8/19/2016Deutsche Bank AktiengesellschaftReiterated RatingBuy$142.00N/A
(Data available from 8/5/2016 forward)
Johnson & Johnson logo
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Read More

Today's Range

Now: $173.36
Low: $173.26
High: $174.59

50 Day Range

MA: $167.65
Low: $161.98
High: $174.39

52 Week Range

Now: $173.36
Low: $133.65
High: $174.59

Volume

4,785,344 shs

Average Volume

6,100,133 shs

Market Capitalization

$456.37 billion

P/E Ratio

26.07

Dividend Yield

2.43%

Beta

0.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Johnson & Johnson?

The following Wall Street sell-side analysts have issued research reports on Johnson & Johnson in the last twelve months: Cantor Fitzgerald, Cowen Inc, Credit Suisse Group AG, JPMorgan Chase & Co., Morgan Stanley, Raymond James, Stifel Nicolaus, SVB Leerink LLC, and Wells Fargo & Company.
View the latest analyst ratings for JNJ.

What is the current price target for Johnson & Johnson?

8 Wall Street analysts have set twelve-month price targets for Johnson & Johnson in the last year. Their average twelve-month price target is $190.38, suggesting a possible upside of 9.8%. Cantor Fitzgerald has the highest price target set, predicting JNJ will reach $200.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $175.00 for Johnson & Johnson in the next year.
View the latest price targets for JNJ.

What is the current consensus analyst rating for Johnson & Johnson?

Johnson & Johnson currently has 2 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe JNJ will outperform the market and that investors should add to their positions of Johnson & Johnson.
View the latest ratings for JNJ.

What other companies compete with Johnson & Johnson?

How do I contact Johnson & Johnson's investor relations team?

Johnson & Johnson's physical mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company's listed phone number is 732-524-0400. The official website for Johnson & Johnson is www.jnj.com.